Midd-term effects of trabeculectomy with mitomycin C in neovascular glaucoma patients.

Hyung,  Sung Min; Kim,  Sang Kook

doi:2001.15.2.98

Korean J Ophthalmol > Volume 15(2); 2001 > Article

Original Article

Korean Journal of Ophthalmology 2001;15(2):98-106.
DOI: https://doi.org/10.3341/kjo.2001.15.2.98 Published online December 30, 2001.

Midd-term effects of trabeculectomy with mitomycin C in neovascular glaucoma patients.

Sung Min Hyung, Sang Kook Kim

Department of Ophthalmology, College of Medicine, Chungbuk National University, heongju, Korea.

Abstract

Twenty four eyes from 23 neovascular glaucoma (NVG) patients, who underwent trabeculectomy with 0.2 or 0.4 mg/ml MMC in least the previous 6 months, were examined in order to evaluate the mid-term effects of a trabeculectomy with mitomycin C (MMC) in NVG. Success defined when an intraocular pressure (IOP) < 22 mmHg and > 5 mmHg with or without medication was observed. The mean IOP was reduced from 46.8+/-12.9 mmHg preoperatively to 18.2+/-12.0 mmHg at the last follow-up (mean = 25.8 months). The overall success rates at 1-, 3-, 6-, 9-, and 12-months after surgery were 71%, 58%, 50%, 29%, 29% respectively. The number of anti-glaucoma medications administered was significantly reduced from 2.6+/-0.7 preoperatively to 0.9+/-1.0 postoperatively (Wilcoxon signed rank test, p = 0.005). In addition both the intraoperative MMC concentration and application time had no influence on lowering the IOP (logistic regression analysis, p = 0.228, 0.910, respectively). There was a similar incidence of postoperative complications in both the success and failure group. These results suggest that a trabeculectomy with MMC is an effective surgical procedure in NVG patients and the MMC concentration is not crucial for reducing the IOP postoperatively.

Key Words: mitomycin C;neovasular glaucoma;trabeculectomy